TY  - JOUR
AU  - Borgia, Sergio M
AU  - Dearden, Janet
AU  - Yoshida, Eric M
AU  - Shafran, Stephen D
AU  - Brown, Ashley
AU  - Ben-Ari, Ziv
AU  - Cramp, Matthew E
AU  - Cooper, Curtis
AU  - Foxton, Matthew
AU  - Rodriguez, Conrado Fernandez
AU  - Esteban, Rafael
AU  - Hyland, Robert
AU  - Lu, Sophia
AU  - Kirby, Brian J
AU  - Meng, Amy
AU  - Markova, Svetlana
AU  - Dvory-Sobol, Hadas
AU  - Osinusi, Anu O
AU  - Bruck, Rafael
AU  - Ampuero, Javier
AU  - Ryder, Stephen D
AU  - Agarwal, Kosh
AU  - Fox, Raymond
AU  - Shaw, David
AU  - Haider, Shariq
AU  - Willems, Bernard
AU  - Lurie, Yoav
AU  - Calleja, Jose Luis
AU  - Gane, Edward J
PY  - 2019
DO  - 10.1016/j.jhep.2019.05.028
UR  - http://hdl.handle.net/10668/14107
T2  - Journal of hepatology
AB  - Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this...
LA  - en
KW  - Chronic hepatitis C infection
KW  - Direct-acting antiviral
KW  - ESRD
KW  - HCV, SVR12, drug safety
KW  - Severe renal impairment
KW  - Antiviral Agents
KW  - Carbamates
KW  - Drug Combinations
KW  - Drug Monitoring
KW  - Female
KW  - Hepacivirus
KW  - Hepatitis C, Chronic
KW  - Heterocyclic Compounds, 4 or More Rings
KW  - Humans
KW  - Kidney Failure, Chronic
KW  - Liver Cirrhosis
KW  - Male
KW  - Middle Aged
KW  - Renal Dialysis
KW  - Sofosbuvir
KW  - Sustained Virologic Response
KW  - Treatment Outcome
TI  - Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
TY  - research article
VL  - 71
ER  -